Sidley Represents Archimed in US$1.1 Billion Acquisition of Esperion Therapeutics

Sidley represented Archimed Group, a leading investment firm focused exclusively on healthcare industries, in the acquisition of Esperion Therapeutics, a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The transaction is valued at up to approximately US$1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones.

The Sidley team was led by David D’Urso, Adam Cromie, Matt Naifeh, and Leigh Rorick (M&A and Private Equity), and includes Arthur Adler, Joshua Rim, Tanvi Sharan, and Tyler Hugh Welsh (M&A and Private Equity); Kristen Smith, Jim Albrecht, and law clerk Jiasi Liu (Global Finance); Asher Rubin, Collin Marshall, Sophia Iams, and Karena Kong (Technology and Life Sciences Transactions); Kayla West and Robert Mandell (Capital Markets); Dustin Anderson and Christian Brause (Tax); Eric Wolf and Ryan McLeod (Employee Benefits and Executive Compensation); Natalie Chan and Ryan Martin (Labor, Employment and Immigration); Lauren Kitces and Stephanie Lim (Privacy and Cybersecurity); Heather Palmer and Sarah Jehl (Environmental); Deeona Gaskin, Kathy Lee, and Julea Lipiz (Food, Drug, and Medical Device); Donielle McCutcheon, Josefine Sommer, Kim Schroer, and Alix Vermulst (Healthcare).